Redux5 mg

Redux was historically indicated as an adjunct to diet and exercise for weight management in obese adults (body mass index ≥ 30 kg/m²) or overweight adults (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity such as type 2 diabetes or dyslipidemia.

Important regulatory note

Redux has been withdrawn from the market in the United States, the European Union, and many other countries since 2010. This action followed clinical trial data (the SCOUT cardiovascular outcomes trial) showing an increased risk of serious cardiovascular events — including heart attack, stroke, and cardiovascular death — particularly in patients with pre-existing cardiovascular disease. As a result, Redux should not be regarded as a routinely recommended or freely available weight-loss treatment.

Availability of Redux varies by country. Where it remains authorized in a particular jurisdiction, it should be used only as a short-term adjunct measure, and only under strict medical supervision that includes a thorough cardiovascular risk assessment before starting treatment and regular monitoring throughout.

Redux is not a substitute for a comprehensive weight-management program and is not intended for cosmetic weight loss.

Where still marketed, Sibutramine is formulated as Sibutramine hydrochloride monohydrate, typically supplied as oral capsules in strengths such as 5 mg, 10 mg, and 15 mg (strengths and available presentations vary by country and manufacturer).

Redux is a centrally-acting agent that was developed for weight management. Pharmacologically it acts as a reuptake inhibitor of serotonin and norepinephrine (with a weaker effect on dopamine reuptake) in the central nervous system, which increases feelings of satiety (fullness) and, to a lesser extent, increases energy expenditure.

Redux is administered orally, once daily, and its active metabolites are largely responsible for its clinical effect.

Because of a well-documented increase in cardiovascular risk identified in post-marketing clinical trials, Redux was withdrawn from sale in numerous countries starting in 2010. Its current regulatory status and availability differ from country to country, and prescribers and patients should confirm local approval status before use.

Anti-obesity agent; centrally-acting appetite suppressant of the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class — Redux is not a stimulant amphetamine-type anorectic.

Mechanism of action

Sibutramine and its two pharmacologically active metabolites (desmethyl metabolites, commonly referred to as M1 and M2) inhibit the reuptake of serotonin (5-HT), norepinephrine, and, to a lesser extent, dopamine at central nervous system synapses.

By prolonging the activity of these neurotransmitters, Sibutramine enhances satiety signaling in the hypothalamus, reducing food intake, and produces a modest increase in thermogenesis (energy expenditure).

Pharmacokinetics

Sibutramine is well absorbed after oral administration and undergoes extensive first-pass hepatic metabolism via CYP3A4 to its active M1 and M2 metabolites, which have longer half-lives than the parent compound. Elimination is primarily via hepatic metabolism with renal excretion of metabolites.

Take Redux capsules by mouth, once daily in the morning, with a full glass of water. May be taken with or without food. Swallow the capsule whole; do not crush, chew, or open it. Take at approximately the same time each day to help maintain consistent blood levels.

• Monoamine oxidase inhibitors (MAOIs): Concomitant use, or use within 2 weeks of stopping an MAOI, is contraindicated due to a serious risk of serotonin syndrome and hypertensive crisis (see Contraindications).
• Other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, lithium, tramadol, dextromethorphan, St. John's Wort): Concomitant use with Redux increases the risk of serotonin syndrome and should generally be avoided.
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir): May increase plasma concentrations of Redux and its active metabolites, potentially increasing cardiovascular and serotonergic risk; combination should be avoided or used with caution and enhanced monitoring.
• Other centrally-acting appetite suppressants or weight-loss agents: Concomitant use with Redux is contraindicated because of additive cardiovascular and serotonergic risk.
• Antihypertensive agents: Redux can raise blood pressure and heart rate and may counteract the effect of antihypertensive therapy; blood pressure should be monitored closely.
• Drugs that prolong the QT interval or other agents affecting cardiac rhythm: Use with caution given the underlying cardiovascular risk profile associated with Redux.

The most commonly reported side effects of Redux include:

• Dry mouth
• Insomnia (difficulty sleeping)
• Constipation
• Headache
• Increased blood pressure and increased heart rate (tachycardia) — see Precautions and Warnings for monitoring requirements
• Dizziness, nausea, and loss of appetite

Less common but serious effects can include serotonin syndrome (when combined with other serotonergic drugs) and, rarely, serious cardiovascular events such as myocardial infarction or stroke — see the regulatory safety information under Indications and Precautions and Warnings.

Redux is contraindicated in pregnancy. It is not intended for use by individuals who are pregnant, breastfeeding, or attempting to conceive. Weight-loss treatment is not appropriate during pregnancy, and any potential effect on fetal development has not been adequately established. If pregnancy occurs or is suspected while a patient is taking Redux, the medicine should be stopped immediately and a physician consulted.

Redux is also contraindicated during breastfeeding, as it is not known whether it passes into breast milk, and the risk to a nursing infant cannot be excluded.

Cardiovascular risk and regulatory withdrawal

Redux has been withdrawn from the market in the United States, the European Union, and many other countries since 2010 because clinical trial data demonstrated an increased risk of serious cardiovascular events (heart attack, stroke) and death, particularly in patients with pre-existing cardiovascular disease. Its availability now varies by country. Where Redux remains available, it should be used only under strict medical supervision that includes a thorough cardiovascular risk assessment before starting and at regular intervals during treatment.

Blood pressure and heart rate monitoring

Redux commonly increases blood pressure and heart rate. Blood pressure and pulse must be checked before starting treatment and monitored regularly (e.g., every 2 weeks for the first 3 months, then periodically) throughout treatment. Redux should be discontinued if a patient develops sustained increases in blood pressure or heart rate.

Serotonin syndrome

Concomitant use of Redux with other serotonergic drugs (see Interactions) can cause serotonin syndrome, a potentially life-threatening condition. Patients should be counseled on symptoms (agitation, rapid heart rate, high body temperature, muscle rigidity, tremor) and instructed to seek urgent care if they occur.

Not for use with a history of cardiovascular disease

Given the established increased cardiovascular risk, Redux must not be used in patients with a history of cardiovascular disease, and should only be considered, where locally approved, under close ongoing medical supervision after a documented cardiovascular risk assessment.

Suspected overdose with Redux is a medical emergency. Anyone who has taken more than the prescribed amount, or who shows symptoms such as a very fast or irregular heartbeat, severe high blood pressure, agitation, confusion, tremor, sweating, or signs of serotonin syndrome, should seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt to treat a suspected overdose at home. Management in a medical facility is supportive and based on the patient's symptoms, generally including cardiovascular monitoring.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

Redux is contraindicated in severe renal impairment. In mild-to-moderate renal impairment, use with caution and close monitoring, as clinical experience is limited.

Hepatic impairment

Redux is contraindicated in severe hepatic impairment, since it undergoes extensive hepatic metabolism. Use with caution in mild-to-moderate hepatic impairment.

Elderly (over 65 years)

Use of Redux in patients over 65 years of age is generally not recommended, as clinical experience is limited and the cardiovascular risk profile of this population raises particular concern (see Precautions and Warnings).

Pediatric patients

See Pediatric Use — safety and efficacy of Redux have not been established in children and adolescents.

Pregnancy and breastfeeding

See Pregnancy and Lactation — Redux is contraindicated.

Where Redux remains authorized for use, treatment should be reassessed regularly. If a patient has not lost at least 5% of baseline body weight after approximately 3 months of therapy, Redux should be discontinued, as continued use is unlikely to be beneficial and unnecessarily prolongs exposure to cardiovascular risk. Historically, total duration of treatment with Redux was limited to a maximum of 1–2 years under most labels, with cardiovascular monitoring required throughout. Long-term or indefinite use is not appropriate.

Anti-obesity agents; Serotonin-Norepinephrine Reuptake Inhibitors (appetite-suppressant subclass) — Sibutramine is the representative agent of this subclass.

Sibutramine and its active metabolites inhibit reuptake of serotonin and norepinephrine (and, weakly, dopamine) in the central nervous system, increasing satiety and modestly increasing energy expenditure, which together reduce food intake and promote weight loss.

C (legacy FDA pregnancy category); nonetheless, use in pregnancy is contraindicated for this indication.

The safety and efficacy of Redux have not been established in children and adolescents under 16 years of age. Redux is not recommended for use in this population, and pediatric obesity should be managed with lifestyle, dietary, and behavioral interventions under specialist supervision rather than with Redux.